India's Drug-Industry Woes No Deterrence To More Than Doubled Market
This article was originally published in PharmAsia News
Executive Summary
Despite its U.S. FDA, regulatory and other problems, India's pharmaceutical market is expected to more than double its value over the next seven years, from $21 billion to $56 billion.
You may also be interested in...
The ICER Process: Allergan Engagement Improves Cost Effectiveness Rating For Ubrelvy
ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.
US FDA’s 2020 Approvals: A Deep Pipeline, And More Of The Expected
Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).
Gene Therapy Approvals By US FDA Could Double In 2020
CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: